Biomarin Pharmaceutical (BSP:B1MR34) Inventories, Finished Goods : R$1,944 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Biomarin Pharmaceutical Inventories, Finished Goods?

Biomarin Pharmaceutical's quarterly finished goods increased from Sep. 2023 (R$1,833 Mil) to Dec. 2023 (R$1,864 Mil) and increased from Dec. 2023 (R$1,864 Mil) to Mar. 2024 (R$1,944 Mil).

Biomarin Pharmaceutical's annual finished goods increased from Dec. 2021 (R$1,590 Mil) to Dec. 2022 (R$1,848 Mil) and increased from Dec. 2022 (R$1,848 Mil) to Dec. 2023 (R$1,864 Mil).

Biomarin Pharmaceutical Inventories, Finished Goods Historical Data

The historical data trend for Biomarin Pharmaceutical's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Inventories, Finished Goods Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Finished Goods

Get a 7-Day Free Trial

1,050.16

1,613.32

1,589.81

1,848.25

1,863.75

Biomarin Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Inventories, Finished Goods	Get a 7-Day Free Trial															1,785.92	1,741.01	1,832.92	1,863.75	1,944.01

Biomarin Pharmaceutical Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Biomarin Pharmaceutical (BSP:B1MR34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (BSP:B1MR34) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

BMRN:USA 1BMRN:Italy BM8:Germany

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

http://www.bmrn.com

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (BSP:B1MR34) Headlines

No Headlines